loading
Schlusskurs vom Vortag:
$8.39
Offen:
$8.42
24-Stunden-Volumen:
141.86K
Relative Volume:
0.10
Marktkapitalisierung:
$732.06M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
11.74
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
-0.79%
1M Leistung:
+28.16%
6M Leistung:
+128.19%
1J Leistung:
+327.86%
1-Tages-Spanne:
Value
$8.10
$8.4429
1-Wochen-Bereich:
Value
$7.84
$8.72
52-Wochen-Spanne:
Value
$1.76
$8.72

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
Firmenname
Amylyx Pharmaceuticals Inc
Name
Telefon
617-683-0917
Name
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Name
Mitarbeiter
123
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
AMLX's Discussions on Twitter

Vergleichen Sie AMLX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AMLX
Amylyx Pharmaceuticals Inc
8.2124 701.54M 380.79M 49.27M 10.68M 0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.55 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.17 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.15 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
581.33 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.94 31.99B 3.81B -644.79M -669.77M -6.24

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Buy
2025-06-24 Eingeleitet Guggenheim Buy
2025-06-17 Eingeleitet Citigroup Buy
2025-05-30 Eingeleitet TD Cowen Buy
2025-04-07 Hochstufung Mizuho Neutral → Outperform
2024-11-18 Hochstufung Robert W. Baird Neutral → Outperform
2024-10-23 Hochstufung BofA Securities Neutral → Buy
2024-03-18 Herabstufung Mizuho Buy → Neutral
2024-03-11 Herabstufung Leerink Partners Outperform → Market Perform
2024-03-11 Herabstufung Robert W. Baird Outperform → Neutral
2024-03-08 Herabstufung Evercore ISI Outperform → In-line
2024-03-08 Herabstufung Goldman Buy → Neutral
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-07-24 Hochstufung Goldman Neutral → Buy
2023-03-31 Eingeleitet Mizuho Buy
2023-01-05 Eingeleitet BofA Securities Buy
2022-05-25 Eingeleitet Citigroup Buy
2022-04-01 Herabstufung Goldman Buy → Neutral
Alle ansehen

Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten

pulisher
Jul 23, 2025

Is Amylyx Pharmaceuticals Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Amylyx Pharmaceuticals Inc. stockExceptional risk-adjusted gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-22 15:57:30 - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential (NASDAQ:AMLX) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 16, 2025

Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 15, 2025
pulisher
Jul 14, 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 14, 2025
pulisher
Jul 14, 2025

TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga

Jul 14, 2025
pulisher
Jul 14, 2025

Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 14, 2025

Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace

Jul 14, 2025
pulisher
Jul 13, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

Breakthrough Drug Cuts Dangerous Post-Bariatric Surgery Events by 64%: Phase 2 Trial Results Revealed - Stock Titan

Jul 13, 2025
pulisher
Jul 12, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Buy” at The Goldman Sachs Group - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 10, 2025

Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential - Investing.com Nigeria

Jul 10, 2025

Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.56
price up icon 3.00%
$36.17
price up icon 0.52%
$103.23
price down icon 0.15%
$27.77
price down icon 0.86%
$114.09
price down icon 0.58%
biotechnology ONC
$295.00
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):